** Credit Suisse upgrades Swiss medical device firm Medacta
MOVE.S to "outperform" from "neutral", citing growth at a
reasonable price
** The broker says that given its confidence in superior
medium-term growth, the industry-low levels at which Medacta is
currently trading offer an entry point
** Credit Suisse says the company is exposed to attractive
end markets and differentiates itself from competitors by
promoting innovative surgical approaches
** The brokerage sees the company's new products and U.S.
exposure as incremental growth drivers
** It says it concludes that recent slower growth is "likely
temporary"
((marta.frackowiak@thomsonreuters.com))